Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies

Abstract

Human B-cell lymphomas, the fourth most common hematologic malignancy, are currently the subject of extensive research. The limited accessibility of biopsies, the heterogeneity among patients, and the subtypes of lymphomas have necessitated the development of animal models to decipher immune escape mechanisms and design new therapies. Here, we summarize the cell lines and murine models used to study lymphomagenesis, the lymphoma microenvironment, and the efficacy of new therapies. These data allow us to understand the role of the immune system in the fight against tumors. Exploring the advantages and limitations of immunocompetent versus immunodeficient models improves our understanding of the molecular and cellular mechanisms of tumor genesis and development as well as the fundamental processes governing the interaction of tumors and their host tissues. We posit that these basic preclinical investigations will open up new and promising approaches to designing better therapies.

Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models

“…In this paper, we are not aiming at assessing the efficacy of CpG as an anti-tumor drug (which has already been demonstrated 7,9,11 ) but to describe a method allowing comparison of bioluminescence datasets. We indeed describe a method to quantify tumor burden intended to help standardize the acquisition protocol for comparing different assays in different places at different times and that does not require computer calculations.…”

“…We applied the luminoscore method to two different mouse lymphoma models 7,8,9 . CpG is an oligonucleotide sequence and a ligand of TLR9, which in turn is an intracellular receptor expressed by numerous cells of the immune system, including dendritic cells, B lymphocytes, monocytes, and natural killer cells.…”

An Innovative Cis-Diammineplatinum (II) Benzene-Polycarboxylic-Acids Complex Inhibits Growth of Burkitt`s Cell Lymphoma In Vitro and In Vivo

“…The results of this study indicated that treatment of mice inoculated with Ramos cells with 47 mg/kg of the test article CBPDA caused a significant reduction of the tumor growth in a 2-week treatment period in NOD-scid mice with experimental Ramos cell B [21][22][23][24][25][26][27][28][29][30]. The mean tumor volume of the treated animals was 53% of the mean tumor volume of the vehicle group.…”

Folic acid-tagged protein nanoemulsions loaded with CORM-2 enhance the survival of mice bearing subcutaneous A20 lymphoma tumors

“…Their therapeutic efficacy was tested in BALB/c mice bearing subcutaneous A20 lymphoma tumors. This syngeneic model mimics human disease in an immunocompetent host with aspects of diffuse large B-cell lymphomas, 28,29 which in our view is clinically relevant. The subcutaneous model has additional advantages, such as providing visual confirmation that mice do have tumors prior to therapy and easy assessment of tumor response or growth over time.…”